Document is current

Article History

Received: 2 May 2025

Accepted: 10 August 2025

First Online: 1 September 2025

Declarations

:

: All eligible individuals with SCA and the HCPs provided informed consent to participate in the interviews and could withdraw at any time. The study was conducted in accordance with the 1964 Declaration of Helsinki.

: Maggie Heinrich, Katja Rudell, Naomi Suminski, Rinchen Doma, Kavita Jarodia, Mahak Jain, and Chris Buckley are employees of Parexel International and have been compensated as consultants by Biohaven Pharmaceuticals Inc. Linda Abetz-Webb received consultancy fees from Parexel International for this study. Jeremy Schmahmann has received compensation as a consultant for Biohaven Pharmaceuticals Inc., is site Principal Investigator for the Biohaven clinical trials NCT03701399 and NCT02960893, and has received an unrestricted grant from Biohaven for an imaging biomarker study in multiple system atrophy. Susan Perlman has been a member of an advisory board or consultant for Biogen, Biohaven Pharmaceuticals, Inc, Erydel, PTC, Quince Therapeutics, Reata Pharmaceuticals, and Steminent. Liana Rosenthal is an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. She engaged in this research as a private consultant or advisor and not in her capacity as a Johns Hopkins faculty member, and was compensated. Liana Rosenthal also receives: research funding support from the NINDS, the Daniel B. and Florence E. Green Family Foundation, and the Macks Family Foundation; programmatic support from the Gordon and Marilyn Macklin Foundation; and salary support for her role as site Principal Investigator for research studies with Biohaven Pharmaceuticals, Pfizer, and EIP Pharma and for serving on the Clinical Events Committee for a research study with Functional Neuromodulation. Liana Rosenthal also serves on steering committees for the Parkinson Study Group’s research study with both UCB and Bial Pharmaceuticals, and on advisory boards for Reata pharmaceuticals, Biogen pharmaceuticals, Biohaven Pharmaceuticals, Merck Healthcare KGaA, and was a one-time consultant for UCB pharmaceuticals.Michele Potashman, Melissa Wolfe-Beiner, Vlad Coric, and Gilbert L’Italien are employed by and hold stock/stock options in Biohaven Pharmaceuticals Inc.